BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 15183903)

  • 1. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.
    Johannessen I; Bieleski L; Urquhart G; Watson SL; Wingate P; Haque T; Crawford DH
    J Med Virol; 2011 Sep; 83(9):1585-96. PubMed ID: 21739450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD.
    Davis JE; Sherritt MA; Bharadwaj M; Morrison LE; Elliott SL; Kear LM; Maddicks-Law J; Kotsimbos T; Gill D; Malouf M; Falk MC; Khanna R; Moss DJ
    Int Immunol; 2004 Jul; 16(7):983-9. PubMed ID: 15159377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH; Russ GR; Coates PT
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Taylor AL; Marcus R; Bradley JA
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E; Cornelissen JJ
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
    Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
    Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.
    O'Reilly RJ; Small TN; Papadopoulos E; Lucas K; Lacerda J; Koulova L
    Springer Semin Immunopathol; 1998; 20(3-4):455-91. PubMed ID: 9870257
    [No Abstract]   [Full Text] [Related]  

  • 11. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
    Lucas KG; Salzman D; Garcia A; Sun Q
    Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants.
    O'Reilly RJ; Lacerda JF; Lucas KG; Rosenfield NS; Small TN; Papadopoulos EB
    Important Adv Oncol; 1996; ():149-66. PubMed ID: 8791134
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
    Mautner J; Bornkamm GW
    Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
    Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
    Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
    Swinnen LJ
    Best Pract Res Clin Haematol; 2006; 19(4):839-47. PubMed ID: 16997187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
    Dolcetti R
    Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases.
    Kim N; Sohn HJ; Oh JH; Jeon YW; Lee HJ; Cho HI; Chung BH; Yang CW; Kim TG; Cho SG
    Int J Hematol; 2018 May; 107(5):596-603. PubMed ID: 29188583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients.
    Wistinghausen B; Gross TG; Bollard C
    Pediatr Hematol Oncol; 2013 Sep; 30(6):520-31. PubMed ID: 23802715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.